Medical devices, healthcare technology and the business of care
510(k) clearance · K260907

BIS Advance pEEG Module

Covidien LP · Decision date Aug 13, 2026

FDA DECISIONK260907

What did the FDA decide?

FDA records K260907 as a 510(k) premarket notification, with a decision dated Aug 13, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Aug 13, 2026

FDA source record

Regulatory record facts

Identifier
K260907
Regulatory pathway
510(k) premarket notification
Applicant
Covidien LP
Product code
OLW
Decision code
SESE
Decision date
Aug 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Index-Generating Electroencephalograph Software.

Applicant
Covidien LP
Product code
OLW
FDA device class
2

FDA decision timeline

  1. K260907 received

    Application receipt date recorded by FDA.

  2. K260907 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code OLW

Product / regulatory recordCompanyPathwayDecision dateSource
Masimo Corporation510(k) clearanceJul 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Covidien LP

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Mansfield, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records